| 0.0002 -0.005 (-96%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.09  |
1-year : | 0.15 |
| Resists | First : | 0.08 |
Second : | 0.13 |
| Pivot price | 0 |
|||
| Supports | First : | 0 |
Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0.04 |
MA(250) : | 0.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 20.9 |
|||
| 52-week | High : | 2.65 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SSKN ] has closed below the lower bollinger band by 43.5%. Bollinger Bands are 89.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0.01 | 0.01 - 0.01 |
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.
Fri, 02 Oct 2026
STRATA Skin Sciences Inc (OTC: SSKN) Share Price, SSKN Stock News, SSKN Share Price & Updates - kalkine.ca
Sat, 01 Aug 2026
Strata Skin Sciences, Inc. Revenue Breakdown – OTC:SSKN - TradingView
Tue, 28 Jul 2026
STRATA Skin Sciences Appoints Erica Jordan as Chief Executive Officer - Quiver Quantitative
Tue, 28 Jul 2026
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer - Yahoo Finance
Fri, 20 Feb 2026
STRATA Skin Sciences (OTCPK:SSKN) - Stock Analysis - Simply Wall Street
Fri, 20 Feb 2026
SSKN Stock Price and Chart — OTC:SSKN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 31.5 (%) |
| Shares Short | 679 (K) |
| Shares Short P.Month | 269 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | -20.4 % |
| Operating Margin | 0.4 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -159 % |
| Qtrly Rev. Growth | -3 % |
| Gross Profit (p.s.) | 3.03 |
| Sales Per Share | 5.21 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|